<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32770128</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study.</ArticleTitle><Pagination><StartPage>13371</StartPage><MedlinePgn>13371</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13371</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-70373-8</ELocationID><Abstract><AbstractText>The use of proton pump inhibitors (PPIs) has been proposed as a potential risk factor for neurodegenerative diseases, but little is known regarding its role in amyotrophic lateral sclerosis (ALS). We therefore aimed to assess the association of PPI use with the subsequent risk of ALS, and performed a register-based nationwide nested case-control study, including 2,484 ALS cases diagnosed during July 2006-December 2013 in Sweden and 10 population controls per case that were individually matched to the case by sex, age, and area of residence. Dispenses and cumulative defined daily doses (cDDDs) of PPIs were extracted from the Swedish Prescribed Drug Register. The association of PPI use with the risk of ALS was assessed using conditional logistic regression, after applying different lag windows to avoid reverse causation. ALS patients were more likely to be dispensed with PPIs before diagnosis than controls. However, previous PPI use was not associated with an increased risk of ALS (OR&#x2009;=&#x2009;1.08, 95% CI 0.97-1.19), and there was no dose-response relationship between cDDDs of PPIs and ALS risk (p&#x2009;=&#x2009;0.0874), after excluding dispenses during the year before ALS diagnosis. The results were similar after excluding dispenses during the 2 or 3&#xa0;years before ALS diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jiangwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Box 210, 17177, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almqvist</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichardt</LastName><ForeName>Berthold</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Austrian Social Health Insurance Fund AT, Eisenstadt, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomschik</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimprich</LastName><ForeName>Fritz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Environmental Medicine, Karolinska Institutet, Box 210, 17177, Stockholm, Sweden. fang.fang@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32770128</ArticleId><ArticleId IdType="pmc">PMC7414209</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-70373-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-70373-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015;7:181&#x2013;193. doi: 10.2147/CLEP.S37505.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257&#x2013;1272. doi: 10.1016/S1474-4422(16)30230-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30230-7</ArticleId><ArticleId IdType="pubmed">27751556</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart M, et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015;11:718&#x2013;726. doi: 10.1016/j.jalz.2015.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.016</ArticleId><ArticleId IdType="pubmed">26045020</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, et al. Lysosomal impairment in Parkinson's disease. Mov. Disord. 2013;28:725&#x2013;732. doi: 10.1002/mds.25462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25462</ArticleId><ArticleId IdType="pmc">PMC5131721</ArticleId><ArticleId IdType="pubmed">23580333</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar A, et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol. Biol. Cell. 2007;18:1490&#x2013;1496. doi: 10.1091/mbc.E06-10-0975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E06-10-0975</ArticleId><ArticleId IdType="pmc">PMC1838985</ArticleId><ArticleId IdType="pubmed">17314396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe DM, et al. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur. J. Neurosci. 2013;37:1949&#x2013;1961. doi: 10.1111/ejn.12169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.12169</ArticleId><ArticleId IdType="pmc">PMC3694736</ArticleId><ArticleId IdType="pubmed">23773064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, et al. Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy. FASEB J. 2017;31:5609&#x2013;5624. doi: 10.1096/fj.201700292RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700292RR</ArticleId><ArticleId IdType="pubmed">28842427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolat Mis MS, Brajkovic S, Frattini E, Di Fonzo A, Corti S. Autophagy in motor neuron disease: Key pathogenetic mechanisms and therapeutic targets. Mol. Cell Neurosci. 2016;72:84&#x2013;90. doi: 10.1016/j.mcn.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2016.01.012</ArticleId><ArticleId IdType="pubmed">26837042</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh JY, Kim HN, Hwang JJ, Kim YH, Park SE. Lysosomal dysfunction in proteinopathic neurodegenerative disorders: Possible therapeutic roles of cAMP and zinc. Mol. Brain. 2019;12:18. doi: 10.1186/s13041-019-0439-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-019-0439-2</ArticleId><ArticleId IdType="pmc">PMC6417073</ArticleId><ArticleId IdType="pubmed">30866990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng FC, Ho YF, Hung LC, Chen CF, Tsai TH. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J. Chromatogr. A. 2002;949:35&#x2013;42. doi: 10.1016/S0021-9673(01)01225-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9673(01)01225-0</ArticleId><ArticleId IdType="pubmed">11999751</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: Potential new clinical use in diagnosis of Alzheimer's disease. J. Alzheimers Dis. 2010;19:573&#x2013;589. doi: 10.3233/JAD-2010-1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1262</ArticleId><ArticleId IdType="pmc">PMC2951486</ArticleId><ArticleId IdType="pubmed">20110603</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio DJ, Nixon RA. Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res. Rev. 2016;32:75&#x2013;88. doi: 10.1016/j.arr.2016.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2016.05.004</ArticleId><ArticleId IdType="pmc">PMC5112157</ArticleId><ArticleId IdType="pubmed">27197071</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J. Gastroenterol. 2013;48:1343&#x2013;1352. doi: 10.1007/s00535-013-0774-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-013-0774-5</ArticleId><ArticleId IdType="pubmed">23478938</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur. J. Neurol. 2012;19:864&#x2013;869. doi: 10.1111/j.1468-1331.2011.03643.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03643.x</ArticleId><ArticleId IdType="pmc">PMC3330170</ArticleId><ArticleId IdType="pubmed">22248366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomm W, et al. Association of proton pump inhibitors with risk of Dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410&#x2013;416. doi: 10.1001/jamaneurol.2015.4791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4791</ArticleId><ArticleId IdType="pubmed">26882076</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenisch B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur. Arch. Psychiatry Clin. Neurosci. 2015;265:419&#x2013;428. doi: 10.1007/s00406-014-0554-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-014-0554-0</ArticleId><ArticleId IdType="pubmed">25341874</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfdanarson OO, et al. Proton-pump inhibitors among adults: A nationwide drug-utilization study. Therap. Adv. Gastroenterol. 2018;11:1756284818777943. doi: 10.1177/1756284818777943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756284818777943</ArticleId><ArticleId IdType="pmc">PMC5977421</ArticleId><ArticleId IdType="pubmed">29872455</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Lewis MA. Proton pump inhibitors and dementia: deciphering the data. Am. J. Gastroenterol. 2017;112:1809&#x2013;1811. doi: 10.1038/ajg.2017.415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2017.415</ArticleId><ArticleId IdType="pubmed">29215629</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipale H, et al. No association between proton pump inhibitor use and risk of Alzheimer's disease. Am. J. Gastroenterol. 2017;112:1802&#x2013;1808. doi: 10.1038/ajg.2017.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2017.196</ArticleId><ArticleId IdType="pubmed">28695906</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin M, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population-based study of consultations, interventions and costs. PLoS ONE. 2017;12:e0179796. doi: 10.1371/journal.pone.0179796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179796</ArticleId><ArticleId IdType="pmc">PMC5480998</ArticleId><ArticleId IdType="pubmed">28640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: A meta-analysis. Gut. 2015;64:1049&#x2013;1057. doi: 10.1136/gutjnl-2014-307843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307843</ArticleId><ArticleId IdType="pubmed">25147201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017;16:144&#x2013;157. doi: 10.1016/S1474-4422(16)30358-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30358-1</ArticleId><ArticleId IdType="pubmed">27964824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J. Pain Res. 2018;11:361&#x2013;374. doi: 10.2147/JPR.S156938.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JPR.S156938</ArticleId><ArticleId IdType="pmc">PMC5817415</ArticleId><ArticleId IdType="pubmed">29491719</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract. Neurol. 2013;13:153&#x2013;164. doi: 10.1136/practneurol-2013-000557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2013-000557</ArticleId><ArticleId IdType="pmc">PMC3664389</ArticleId><ArticleId IdType="pubmed">23616620</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2&#x2013;3. doi: 10.1136/bmj.39406.449456.BE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39406.449456.BE</ArticleId><ArticleId IdType="pmc">PMC2174763</ArticleId><ArticleId IdType="pubmed">18174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: What the clinician needs to know. Therap Adv. Gastroenterol. 2012;5:219&#x2013;232. doi: 10.1177/1756283X12437358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X12437358</ArticleId><ArticleId IdType="pmc">PMC3388523</ArticleId><ArticleId IdType="pubmed">22778788</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, et al. Risk of death among users of Proton Pump Inhibitors: A longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735. doi: 10.1136/bmjopen-2016-015735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-015735</ArticleId><ArticleId IdType="pmc">PMC5642790</ArticleId><ArticleId IdType="pubmed">28676480</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, et al. Increased risk of death associated with the use of proton-pump inhibitors in patients with dementia and controls&#x2014;a pharmacoepidemiological claims data analysis. Eur. J. Neurol. 2020 doi: 10.1111/ene.14252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14252</ArticleId><ArticleId IdType="pmc">PMC7496707</ArticleId><ArticleId IdType="pubmed">32281706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, et al. Associations between co-medications and survival in ALS-a cohort study from Austria. J. Neurol. 2015;262:1698&#x2013;1705. doi: 10.1007/s00415-015-7767-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7767-7</ArticleId><ArticleId IdType="pubmed">25957641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann. Neurol. 2017;81:718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnott SJ, Polinski JM, Byrne S, Gagne JJ. Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class. J. Clin. Epidemiol. 2016;69:107&#x2013;113. doi: 10.1016/j.jclinepi.2015.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.05.026</ArticleId><ArticleId IdType="pmc">PMC4881302</ArticleId><ArticleId IdType="pubmed">26146090</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin. Pharmacol. Ther. 2009;85:103&#x2013;107. doi: 10.1038/clpt.2008.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2008.211</ArticleId><ArticleId IdType="pubmed">19037198</ArticleId></ArticleIdList></Reference><Reference><Citation>Yood MU, et al. Using prescription claims data for drugs available over-the-counter (OTC) Pharmacoepidemiol. Drug Saf. 2007;16:961&#x2013;968. doi: 10.1002/pds.1454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1454</ArticleId><ArticleId IdType="pubmed">17654746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. Eur. J. Epidemiol. 2009;24:659&#x2013;667. doi: 10.1007/s10654-009-9350-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-009-9350-y</ArticleId><ArticleId IdType="pmc">PMC2773709</ArticleId><ArticleId IdType="pubmed">19504049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi: 10.1186/1471-2458-11-450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-450</ArticleId><ArticleId IdType="pmc">PMC3142234</ArticleId><ArticleId IdType="pubmed">21658213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin JH, Gail MH. Biased selection of controls for case&#x2013;control analyses of cohort studies. Biometrics. 1984;40:63&#x2013;75. doi: 10.2307/2530744.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2530744</ArticleId><ArticleId IdType="pubmed">6375751</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettermark B, et al. The new Swedish Prescribed Drug Register&#x2013;opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Saf. 2007;16:726&#x2013;735. doi: 10.1002/pds.1294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1294</ArticleId><ArticleId IdType="pubmed">16897791</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, et al. The Swedish motor neuron disease quality registry. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2018;19:528&#x2013;537. doi: 10.1080/21678421.2018.1497065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497065</ArticleId><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>